Exelixis Inc
NASDAQ:EXEL 4:00:00 PM EDT
| Market Cap (Intraday) | 12.02B |
| Current PE | 18.68 |
| Forward PE | 16.57 |
| 2yr Forward PE | 13.86 |
| 10-Day MA | $43.32 |
| 50-Day MA | $41.18 |
| 200-Day MA | $35.27 |
Exelixis Inc Stock, NASDAQ:EXEL
1851 Harbor Bay Parkway, Alameda, California 94502
United States of America
Phone: +1.650.837.7000
Number of Employees: 1147
Description
Exelixis, Inc. operates as an oncology company, which focuses on discovering, developing, and commercialization of new medicines for difficult-to-treat cancers. Its products include cabometyx, cometriq, and cotellic. The company was founded by Stelios Papadopoulos on November 15, 1994, and is headquartered in Alameda, CA.